|
China’s new Alzheimer’s disease drug “Nine Phase One” included in medical insurance can provide medicines for millions of patients annually |
China News Service, Beijing, December 3 (Reporter Sun Zifa) China’s “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021)” (medical insurance drug catalog) announced on December 3, China’s original treatment Alzheimer The new disease drug Ganlut Sodium Capsules (trade name “Nine Phase One”) was included in the catalog. At present, the production capacity of the “Nine Phase One” can meet the needs of approximately 1 million patients per year.
After the “Nine Phase One” enters the medical insurance drug catalog, the cost of medication for patients will be reduced from 3,580 yuan (RMB, the same below) per month to 1,184 yuan per month based on 4 boxes per month, which is calculated on the basis of an average of 50% medical insurance reimbursement ratio for outpatients nationwide. The monthly self-payment is less than 600 yuan, and the cost of direct medication is greatly reduced.
Dr. Li Jinhe, executive deputy general manager of Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd., a “Nine Phase One” R&D and production company, said that the current production capacity of “Nine Phase One” can meet the needs of approximately 1 million patients per year. “The cost and effect advantages will be further highlighted. With the decline in medication expenditure, more patients are expected to use the drug for a long time. In the future, Green Valley will ensure the production and channel supply of new drugs after they enter the medical insurance, guarantee the quality, quantity, and supply at the new medical insurance implementation price, and meet the needs of the majority of patients, thereby reducing the impact of Alzheimer’s disease on patients, families and The burden of society.
ChinaAcademy of Sciencesacademician, Chen Kaixian, deputy chief technical engineer of the major science and technology project of the national “Major New Drug Creation” pointed out that the “Nine Phase One” is a major landmark achievement in the development of new drugs. This time being included in medical insurance is a great boon for patients. There is a huge unmet need for treatment in the prevention and treatment of Alzheimer’s in China. In the long term, being included in medical insurance as a therapeutic drug of higher clinical value will help to alleviate China’s overall social and economic burden in the field of this disease. .
According to Green Valley, in April 2020, the “Nine Phase One” international multi-center phase three clinical trial application was approved by the U.S. Food and Drug Administration (FDA). Since then, it has been approved by 10 countries including Canada, Australia, France, and the Czech Republic. / Approved by the Regional Drug Administration, 139 clinical centers have been launched globally, 817 patients have been screened, and 234 subjects have been randomly enrolled. The trial is planned to be completed in 2025, and the overseas new drug registration and marketing work will be carried out afterwards.
It is understood that Alzheimer’s disease, commonly known as Alzheimer’s disease, is a serious neurodegenerative disease that causes progressive and persistent cognitive impairment in patients, and eventually loses the ability to work and live. It is also a follow-up to cardiovascular and cerebrovascular diseases and malignant After tumors, the third leading cause of disability and death among the elderly.
China’s latest version of the National Medical Insurance Drug List will be officially implemented on January 1, 2022. (over)
Special statement: The reprinting of this article is only for the purpose of disseminating information, and does not mean that it represents the views of this website or confirms the authenticity of its content; if other media, websites or individuals reprint and use from this website, they must retain the information indicated on this website “Source”, and bear legal responsibility such as copyright; if the author does not want to be reprinted or contact reprinting fees and other matters, please contact us.